ABBV - AbbVie Inc.

NYSE - NYSE Delayed Price. Currency in USD
89.50
+2.30 (+2.64%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close87.20
Open88.45
Bid88.75 x 1300
Ask0.00 x 900
Day's Range86.92 - 89.79
52 Week Range77.50 - 125.86
Volume6,190,025
Avg. Volume7,143,258
Market Cap134.628B
Beta (3Y Monthly)1.44
PE Ratio (TTM)18.69
EPS (TTM)4.79
Earnings DateJan 25, 2019
Forward Dividend & Yield4.28 (4.91%)
Ex-Dividend Date2019-01-14
1y Target Est97.18
Trade prices are not sourced from all markets
  • Earnings, Davos - What to know in the week ahead
    Yahoo Finance12 hours ago

    Earnings, Davos - What to know in the week ahead

    World Economic Forum gathers in Davos, Switzerland, government shutdown continues and earnings week two, here's what you need to know next week.

  • Better Buy: AbbVie vs. Johnson & Johnson
    Motley Fool15 hours ago

    Better Buy: AbbVie vs. Johnson & Johnson

    Which stock wins in a one-on-one matchup between these two big drugmakers?

  • Top Marijuana Stocks That Pay Dividends
    Investopedia21 hours ago

    Top Marijuana Stocks That Pay Dividends

    When most people think of marijuana stocks, the last thing they think of is dividends. The legal marijuana industry is still very young, and new companies in growing industries need money to expand. Furthermore, U.S. investors in the marijuana space tend to currently focus on a handful of Canadian companies which have enjoyed the opportunity to list on U.S. exchanges.

  • Barrons.com2 days ago

    Lockheed Martin and Other Big Names From a Small-Caps Specialist

    The founder and president of Delphi Management likes U.S. Bancorp, AbbVie, Disney, Lockheed Martin, Hercules Capital, and, for the faint of heart, U.S. Treasury paper.

  • Reuters2 days ago

    AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study

    AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. The treatment, Imbruvica, failed to show statistically significant improvement in progression-free survival (PFS) or overall survival in metastatic pancreatic cancer patients, compared with the combination of placebo and two chemotherapy agents. The American Cancer society estimates that pancreatic cancer accounts for about 3 percent of all cancers in the United States and about 7 percent of all cancer deaths, and expects that 56,770 people will be diagnosed with pancreatic cancer in 2019.

  • Reuters2 days ago

    AbbVie's cancer drug fails to meet main goal in late-stage study

    AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. The treatment, ibrutinib, ...

  • PR Newswire2 days ago

    AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer

    -- The RESOLVE (PCYC-1137) trial evaluated ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents -- The study did ...

  • AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks3 days ago

    AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

    AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Can AbbVie (ABBV) Keep the Earnings Surprise Streak Alive?
    Zacks3 days ago

    Can AbbVie (ABBV) Keep the Earnings Surprise Streak Alive?

    AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Are you a Tortoise or a Hare Investor?
    Zacks3 days ago

    Are you a Tortoise or a Hare Investor?

    Some love the latest IPO and others invest in the tried and true. All investors should know their investing style

  • Pacira's Study on Exparel Label Expansion Meets Endpoints
    Zacks3 days ago

    Pacira's Study on Exparel Label Expansion Meets Endpoints

    Pacira's (PCRX) phase IV study of its lead drug Exparel in patients undergoing Cesarean section achieves primary endpoint.

  • Zacks4 days ago

    Banks Keep Stocks Moving Higher

    Banks Keep Stocks Moving Higher

  • Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon
    Zacks4 days ago

    Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon

    Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon

  • Markit4 days ago

    See what the IHS Markit Score report has to say about AbbVie Inc.

    # AbbVie Inc ### NYSE:ABBV View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for ABBV with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABBV. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $8.00 billion over the last one-month into ETFs that hold ABBV are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.